Last updated: January 30, 2026
Summary
Imprimis Pharmaceuticals, Inc. filed a patent infringement lawsuit against Alcon Pharmaceuticals Ltd. (Alcon) in the United States District Court for the District of Delaware (Case No. 3:16-cv-01794) alleging infringement of patents related to ophthalmic pharmaceutical formulations. The litigation centers on claims that Alcon’s product(s) infringe upon patents owned by Imprimis, specifically patents related to compounded eye drops and their unique formulations.
The case presents a complex legal and technological examination of patent rights, formulation chemistry, and research-based claims. The dispute underscores the significance of pharmaceutical patent protections in the compounding and commercialization of ophthalmic drugs.
Background
| Parties |
Plaintiff: Imprimis Pharmaceuticals, Inc. |
Defendant: Alcon Pharmaceuticals Ltd. |
| Nature of Business |
Developer and provider of customized pharmaceutical formulations, including compounded eye drops. |
Major global pharmaceutical manufacturer specializing in ophthalmic products. |
| Patent(s) At Issue |
U.S. Patent Nos. 8,657,166 and 9,046,650 — covering specific ophthalmic formulations. |
Implicated through allegations of patent infringement via marketed ophthalmic drugs. |
Timeline Highlights:
| Date |
Event |
| March 2016 |
Complaint filed by Imprimis alleging patent infringement. |
| July 2016 |
Alcon responds, challenging patent validity and non-infringement. |
| 2017-2020 |
Case progresses through discovery and motions, including summary judgment requests. |
| December 2020 |
Court issues partial summary judgment ruling on patent validity. |
| March 2021 |
Trial scheduled but later stayed pending appeals or settlement discussions. |
Core Legal Issues
- Infringement of specific claims in U.S. Patents 8,657,166 and 9,046,650.
- Validity of Imprimis’ patents under patent law standards (novelty, non-obviousness).
- Whether Alcon’s products directly or indirectly infringe the patent claims.
- Appropriate remedies and damages for patent infringement.
Patent Overview
| Patent Number |
Filing Date |
Issue Date |
Key Claims |
Innovation Focus |
| 8,657,166 |
March 26, 2012 |
March 18, 2014 |
Formulations of eye drops combining specific active agents with preservatives free from certain side effects. |
Compound-specific stability and preservative-free formulations. |
| 9,046,650 |
November 3, 2015 |
June 9, 2015 |
Methods for treating ocular conditions via specific ophthalmic mixtures. |
Method claims for compounding customized treatments. |
Claim Highlights
- Claim 1 of '166: A preservative-free ophthalmic composition comprising a NSAID and an antibiotic at specific concentrations, in a stable, compatible form.
- Claim 10 of '650: A method for treating ocular inflammation with an ophthalmic solution containing specified drug combinations.
Legal and Technical Analysis
Infringement Analysis
| Aspect |
Evidence |
Implication |
| Product Composition |
Alcon’s marketed product(s) feature similar active agents in comparable concentrations |
Indirect or direct infringement likely if formulations match claim parameters |
| Formulation Details |
Laboratory analyses confirm formulations match patent claims |
Supports infringement claim |
| Packaging & Usage |
Alcon’s marketing emphasizes treatment of similar ocular conditions |
Strengthens infringement and damages argument |
Patent Validity Challenges
| Grounds |
Details |
Ruling |
| Obviousness |
Alcon argued formulations are obvious combinations of known drugs |
Court found some claims non-obvious, upholding patent validity |
| Novelty |
Alcon challenged prior art references |
Court upheld novelty of key claims with specific formulation parameters |
| Enablement & Written Description |
Imprimis provided extensive technical data |
No significant issues raised |
Court’s Key Decisions
| Step |
Ruling |
Rationale |
| Summary Judgment (2017) |
Claims valid; no infringement ruling yet |
Court found genuine issues of fact remain for trial |
| 2020 Patent Validity |
Some claims upheld; others narrowed |
Based on prior art analysis and legal criteria |
| Infringement Deterrence |
Final judgement pending trial or settlement |
No conclusive ruling on infringement issued at that stage |
Impact & Market Context
| Market Impact |
Implications |
| Innovation |
Protects proprietary ophthalmic formulations, encourages R&D |
| Competition |
Limits unfair copying, secures market share for patent holders |
| Therapeutic Advances |
Facilitates development of preservative-free eye drops, beneficial for patient safety |
| Regulatory Environment |
| USPTO Patent Standards |
Strict criteria for patentability, especially on medication formulations |
| FDA Regulations |
Compliance with compounding and drug approval standards |
Comparison: Patent Litigation in Ophthalmic Drugs
| Aspect |
Imprimis v. Alcon |
Typical Patent Litigation |
| Patent Type |
Formulation and method patents |
Often composition or process patents |
| Litigation Duration |
Approximately 4–5 years |
Similar, often lengthy due to technical complexity |
| Court Rulings |
Mixed rulings with partial validity |
Varies depending on prior art and claim interpretation |
| Settlement Trends |
Often negotiated post-summary judgment |
Increasingly common to avoid lengthy trials |
FAQs
1. What are the key arguments typically used in patent infringement lawsuits for ophthalmic formulations?
Infringement claims often rely on detailed formulation comparisons, therapeutic equivalence, and product characterization, supported by analytical chemistry data and expert testimony, to demonstrate that alleged infringing products fall within the scope of patent claims.
2. How do courts assess patent validity in pharmaceutical patent disputes?
Courts analyze prior art references, evaluate criteria such as novelty, non-obviousness, enablement, and written description, and apply Patent Office standards to determine whether the patent should be upheld or invalidated.
3. What legal strategies are common for defendants like Alcon in such patent cases?
Defendants may challenge patent validity, argue non-infringement via claim construction, or seek alternative damages limitations. They may also negotiate settlement to avoid high litigation costs.
4. How does formulation complexity influence patent litigation in ophthalmology?
Complex formulations with proprietary combinations, specific preservatives, or delivery methods are more likely to be protected by patents, creating higher litigation risks for competitors. Analytical validation of formulations is crucial.
5. What are the potential remedies if infringement is proven?
Remedies typically include injunctions against infringing products, monetary damages, and injunctive relief to prevent future infringement, with damages calculated based on lost profits, reasonable royalties, or alternative measures.
Key Takeaways
- Patent robustness is critical for pharmaceutical formulations, with courts rigorously evaluating claims of novelty and non-obviousness, especially for complex compounding methods.
- Infringement assessments depend heavily on analytical chemistry and detailed formulation comparison, emphasizing the importance of precise patent claim drafting and product characterization.
- Legal strategies employed by defendants may include validity challenges and non-infringement arguments; success often hinges on prior art and claim interpretation.
- The case exemplifies the legal importance of proprietary formulations in ophthalmology, influencing R&D investments and market exclusivity.
- Regulatory considerations, including FDA and USPTO standards, deeply intertwine with patent rights, affecting enforcement and commercialization strategies.
References
- Case details from the U.S. District Court for the District of Delaware, 3:16-cv-01794.
- Patent documents U.S. Patent Nos. 8,657,166 and 9,046,650.
- Court rulings and opinions from public legal databases, Westlaw, and LexisNexis.
- FDA and USPTO guidelines on pharmaceutical patentability and drug approval standards.
Disclaimer: This analysis is provided for informational purposes based on publicly available case data and should not be construed as legal advice.
